A. D. Leo

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.

P. Queirolo, B. Giannotti, A. Di Leo, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.

C. Sotiriou, D. Larsimont, M. Piccart, 2004, International journal of oncology.

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

M. Piccart, F. Cardoso, C. Lohrisch, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.

D. Larsimont, M. Piccart, J. Isola, 2002, Journal of clinical pathology.

The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions.

M. Piccart, F. Cardoso, M. Paesmans, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

C. Sotiriou, S. Loi, K. Willard-Gallo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

D. Larsimont, M. Piccart, N. O’higgins, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.